CN1240382C - 以吡啶并吲哚酮衍生物和抗癌剂为基的药物组合 - Google Patents

以吡啶并吲哚酮衍生物和抗癌剂为基的药物组合 Download PDF

Info

Publication number: CN1240382C
Authority: CN; China
Prior art keywords: methyl; chemical compound; hydrogen atom; represent hydrogen; pyrido
Prior art date: 2001-04-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CNB028088980A

Other languages

English (en)

Chinese (zh)

Other versions

CN1505510A (zh

Inventor

B·布里

P·卡塞拉斯

J·－M·德罗克

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Sanofi Aventis France

Original Assignee

Sanofi Aventis France

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-04-27

Filing date

2002-04-26

Publication date

2006-02-08

2002-04-26 Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France

2004-06-16 Publication of CN1505510A publication Critical patent/CN1505510A/zh

2006-02-08 Application granted granted Critical

2006-02-08 Publication of CN1240382C publication Critical patent/CN1240382C/zh

2022-04-26 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CNB028088980A 2001-04-27 2002-04-26 以吡啶并吲哚酮衍生物和抗癌剂为基的药物组合 Expired - Fee Related CN1240382C (zh)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR0105843A FR2823975B1 (fr)	2001-04-27	2001-04-27	Nouvelle utilisation de pyridoindolone
FR01/05843		2001-04-27

Publications (2)

Publication Number	Publication Date
CN1505510A CN1505510A (zh)	2004-06-16
CN1240382C true CN1240382C (zh)	2006-02-08

Family

ID=8862882

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
CNB028088980A Expired - Fee Related CN1240382C (zh)	2001-04-27	2002-04-26	以吡啶并吲哚酮衍生物和抗癌剂为基的药物组合
CNA028089596A Pending CN1505511A (zh)	2001-04-27	2002-04-26	吡啶并吲哚酮类衍生物用于制备药物的用途

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
CNA028089596A Pending CN1505511A (zh)	2001-04-27	2002-04-26	吡啶并吲哚酮类衍生物用于制备药物的用途

Country Status (34)

Country	Link
US (3)	US7524857B2 (da)
EP (2)	EP1385513B1 (da)
JP (2)	JP2004528343A (da)
KR (1)	KR100847413B1 (da)
CN (2)	CN1240382C (da)
AR (1)	AR034313A1 (da)
AT (2)	ATE314070T1 (da)
BG (2)	BG108260A (da)
BR (1)	BR0209138A (da)
CA (2)	CA2444334A1 (da)
CY (1)	CY1105813T1 (da)
CZ (2)	CZ299465B6 (da)
DE (2)	DE60214533T2 (da)
DK (2)	DK1385513T3 (da)
EA (1)	EA005930B1 (da)
EE (2)	EE200300466A (da)
ES (2)	ES2254683T3 (da)
FR (1)	FR2823975B1 (da)
HK (2)	HK1059895A1 (da)
HU (2)	HUP0400745A2 (da)
IL (4)	IL158312A0 (da)
IS (1)	IS2441B (da)
MX (1)	MXPA03009639A (da)
NO (2)	NO20034785L (da)
NZ (1)	NZ528671A (da)
PL (2)	PL366910A1 (da)
PT (2)	PT1385512E (da)
RS (2)	RS50791B (da)
RU (1)	RU2292888C9 (da)
SK (2)	SK13242003A3 (da)
TW (1)	TWI252104B (da)
UA (1)	UA74876C2 (da)
WO (2)	WO2002087575A1 (da)
ZA (1)	ZA200307785B (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2823975B1 (fr) *	2001-04-27	2003-05-30	Sanofi Synthelabo	Nouvelle utilisation de pyridoindolone
US7456193B2 (en) *	2002-10-23	2008-11-25	Sanofi-Aventis	Pyridoindolone derivatives substituted in the 3-position by a heterocyclic group, their preparation and their application in therapeutics
FR2846329B1 (fr) *	2002-10-23	2004-12-03	Sanofi Synthelabo	Derives de pyridoindolone substitues en -3 par un phenyle, leur preparation et leur application en therapeutique
FR2869316B1 (fr) *	2004-04-21	2006-06-02	Sanofi Synthelabo	Derives de pyridoindolone substitues en -6, leur preparation et leur application en therapeutique.
FR2892416B1 (fr) *	2005-10-20	2008-06-27	Sanofi Aventis Sa	Derives de 6-heteroarylpyridoindolone, leur preparation et leur application en therapeutique

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1268772A (en) *	1968-03-15	1972-03-29	Glaxo Lab Ltd	NOVEL alpha-CARBOLINE DERIVATIVES, THE PREPARATION THEREOF AND COMPOSITIONS CONTAINING THE SAME
US4263304A (en) *	1978-06-05	1981-04-21	Sumitomo Chemical Company, Limited	7 H-indolo[2,3-c]isoquinolines
SU833971A1 (ru) *	1979-07-10	1981-05-30	Ленинградский Химико-Фармацевтическийинститут	Способ получени 3-фенил-2-оксо- - КАРбОлиНОВ
SU833972A1 (ru)	1979-10-26	1981-05-30	Институт Физико-Органической Химиии Углехимии Ah Украинской Ccp	Имидазо(4,5-с)пиридиний иодиды вКАчЕСТВЕ пРОМЕжуТОчНыХ пРОдуКТОВ дл СиНТЕзА фуНгицидОВ
FR2595701B1 (fr) *	1986-03-17	1988-07-01	Sanofi Sa	Derives du pyrido-indole, leur application a titre de medicaments et les compositions les renfermant
US5035252A (en) *	1990-12-14	1991-07-30	Mondre Steven J	Nicotine-containing dental floss
EP0755454B1 (en) *	1994-04-13	2008-02-13	The Rockefeller University	Aav-mediated delivery of dna to cells of the nervous system
DE19502753A1 (de) *	1995-01-23	1996-07-25	Schering Ag	Neue 9H-Pyrido[3,4-b]indol-Derivate
US6486177B2 (en) *	1995-12-04	2002-11-26	Celgene Corporation	Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
FR2765581B1 (fr) *	1997-07-03	1999-08-06	Synthelabo	Derives de 3-aryl-1,9-dihydro-2h-pyrido[2,3-b]indol-2-one, leur preparation et leur application en therapeutique
FR2765582B1 (fr) *	1997-07-03	1999-08-06	Synthelabo	Derives de 3-alkyl-1,9-dihydro-2h-pyrido[2,3-b]indol-2-one leur preparation et leur application en therapeutique
JP2002510686A (ja) *	1998-04-02	2002-04-09	ニューロゲンコーポレイション	アミノアルキルで置換された５，６，７，８−テトラヒドロ−９Ｈ−ピリジノ［２，３−ｂ］インドール及び５，６，７，８−テトラヒドロ−９Ｈピリミジノ［４，５−Ｂ］インドール誘導体：ＣＲＦ１特異的配位子
IT1313592B1 (it)	1999-08-03	2002-09-09	Novuspharma Spa	Derivati di 1h-pirido 3,4-b indol-1-one.
US20020156016A1 (en) *	2001-03-30	2002-10-24	Gerald Minuk	Control of cell growth by altering cell membrane potentials
FR2823975B1 (fr) *	2001-04-27	2003-05-30	Sanofi Synthelabo	Nouvelle utilisation de pyridoindolone
FR2846329B1 (fr)	2002-10-23	2004-12-03	Sanofi Synthelabo	Derives de pyridoindolone substitues en -3 par un phenyle, leur preparation et leur application en therapeutique
FR2846330B1 (fr)	2002-10-23	2004-12-03	Sanofi Synthelabo	Derives de pyridoindolone substitues en -3 par groupe heterocyclique, leur preparation et leur application en therapeutique
US6958347B2 (en)	2002-12-18	2005-10-25	Pfizer Inc.	Aminophenanthridinone and aminophenanthridine as NPY-5 antagonists
FR2869316B1 (fr) *	2004-04-21	2006-06-02	Sanofi Synthelabo	Derives de pyridoindolone substitues en -6, leur preparation et leur application en therapeutique.
FR2892416B1 (fr)	2005-10-20	2008-06-27	Sanofi Aventis Sa	Derives de 6-heteroarylpyridoindolone, leur preparation et leur application en therapeutique

2001
- 2001-04-27 FR FR0105843A patent/FR2823975B1/fr not_active Expired - Fee Related
2002
- 2002-04-26 EP EP02735502A patent/EP1385513B1/fr not_active Expired - Lifetime
- 2002-04-26 KR KR1020037013925A patent/KR100847413B1/ko not_active IP Right Cessation
- 2002-04-26 AT AT02732841T patent/ATE314070T1/de not_active IP Right Cessation
- 2002-04-26 DK DK02735502T patent/DK1385513T3/da active
- 2002-04-26 RS YUP-839/03A patent/RS50791B/sr unknown
- 2002-04-26 PT PT02732841T patent/PT1385512E/pt unknown
- 2002-04-26 CA CA002444334A patent/CA2444334A1/fr not_active Abandoned
- 2002-04-26 CZ CZ20032910A patent/CZ299465B6/cs not_active IP Right Cessation
- 2002-04-26 HU HU0400745A patent/HUP0400745A2/hu unknown
- 2002-04-26 IL IL15831202A patent/IL158312A0/xx unknown
- 2002-04-26 MX MXPA03009639A patent/MXPA03009639A/es active IP Right Grant
- 2002-04-26 AR ARP020101521A patent/AR034313A1/es unknown
- 2002-04-26 TW TW091108716A patent/TWI252104B/zh not_active IP Right Cessation
- 2002-04-26 NZ NZ528671A patent/NZ528671A/en unknown
- 2002-04-26 WO PCT/FR2002/001450 patent/WO2002087575A1/fr active IP Right Grant
- 2002-04-26 US US10/476,321 patent/US7524857B2/en active Active
- 2002-04-26 ES ES02732841T patent/ES2254683T3/es not_active Expired - Lifetime
- 2002-04-26 DE DE60214533T patent/DE60214533T2/de not_active Expired - Lifetime
- 2002-04-26 IL IL15826602A patent/IL158266A0/xx unknown
- 2002-04-26 RU RU2003130376/15A patent/RU2292888C9/ru active
- 2002-04-26 SK SK1324-2003A patent/SK13242003A3/sk unknown
- 2002-04-26 PT PT02735502T patent/PT1385513E/pt unknown
- 2002-04-26 CZ CZ20032909A patent/CZ295224B6/cs not_active IP Right Cessation
- 2002-04-26 CA CA002443012A patent/CA2443012C/fr not_active Expired - Fee Related
- 2002-04-26 DE DE60208365T patent/DE60208365T2/de not_active Expired - Lifetime
- 2002-04-26 WO PCT/FR2002/001449 patent/WO2002087574A2/fr active IP Right Grant
- 2002-04-26 CN CNB028088980A patent/CN1240382C/zh not_active Expired - Fee Related
- 2002-04-26 CN CNA028089596A patent/CN1505511A/zh active Pending
- 2002-04-26 EE EEP200300466A patent/EE200300466A/xx unknown
- 2002-04-26 ES ES02735502T patent/ES2271264T3/es not_active Expired - Lifetime
- 2002-04-26 EP EP02732841A patent/EP1385512B1/fr not_active Expired - Lifetime
- 2002-04-26 SK SK1325-2003A patent/SK13252003A3/sk unknown
- 2002-04-26 JP JP2002584919A patent/JP2004528343A/ja active Pending
- 2002-04-26 PL PL02366910A patent/PL366910A1/xx unknown
- 2002-04-26 AT AT02735502T patent/ATE338548T1/de not_active IP Right Cessation
- 2002-04-26 EA EA200301062A patent/EA005930B1/ru not_active IP Right Cessation
- 2002-04-26 RS YUP-834/03A patent/RS50790B/sr unknown
- 2002-04-26 JP JP2002584920A patent/JP2004531538A/ja active Pending
- 2002-04-26 US US10/476,322 patent/US6967203B2/en not_active Expired - Lifetime
- 2002-04-26 PL PL02366916A patent/PL366916A1/xx not_active IP Right Cessation
- 2002-04-26 HU HU0400744A patent/HUP0400744A2/hu unknown
- 2002-04-26 BR BR0209138-0A patent/BR0209138A/pt not_active IP Right Cessation
- 2002-04-26 DK DK02732841T patent/DK1385512T3/da active
- 2002-04-26 EE EEP200300465A patent/EE200300465A/xx unknown
- 2002-04-26 UA UA2003109248A patent/UA74876C2/uk unknown
2003
- 2003-10-02 IL IL158266A patent/IL158266A/en not_active IP Right Cessation
- 2003-10-06 ZA ZA200307785A patent/ZA200307785B/en unknown
- 2003-10-08 IL IL158312A patent/IL158312A/en not_active IP Right Cessation
- 2003-10-09 IS IS6984A patent/IS2441B/is unknown
- 2003-10-13 BG BG108260A patent/BG108260A/bg unknown
- 2003-10-13 BG BG108261A patent/BG108261A/bg unknown
- 2003-10-24 NO NO20034785A patent/NO20034785L/no not_active Application Discontinuation
- 2003-10-24 NO NO20034787A patent/NO20034787L/no not_active Application Discontinuation
2004
- 2004-04-20 HK HK04102775A patent/HK1059895A1/xx not_active IP Right Cessation
- 2004-05-03 HK HK04103103A patent/HK1060066A1/xx not_active IP Right Cessation
2005
- 2005-08-15 US US11/204,275 patent/US7160895B2/en not_active Expired - Lifetime
2006
- 2006-11-30 CY CY20061101725T patent/CY1105813T1/el unknown

Also Published As

Publication number	Publication date
RU2292888C2 (ru)	2007-02-10
EP1385513B1 (fr)	2006-09-06
RS50791B (sr)	2010-08-31
EP1385512A2 (fr)	2004-02-04
FR2823975B1 (fr)	2003-05-30
TWI252104B (en)	2006-04-01
WO2002087574A2 (fr)	2002-11-07
EP1385512B1 (fr)	2005-12-28
NO20034785L (no)	2003-12-23
RU2292888C9 (ru)	2007-06-20
ATE338548T1 (de)	2006-09-15
BG108261A (bg)	2004-12-30
ES2271264T3 (es)	2007-04-16
CN1505510A (zh)	2004-06-16
BG108260A (bg)	2004-12-30
KR20040015138A (ko)	2004-02-18
EE200300466A (et)	2003-12-15
HUP0400744A2 (hu)	2004-06-28
EA005930B1 (ru)	2005-08-25
CA2443012A1 (en)	2002-11-07
NZ528671A (en)	2004-06-25
CA2444334A1 (fr)	2002-11-07
JP2004528343A (ja)	2004-09-16
IS6984A (is)	2003-10-09
IL158266A0 (en)	2004-05-12
PT1385512E (pt)	2006-05-31
NO20034787L (no)	2003-12-23
SK13252003A3 (sk)	2004-03-02
DK1385513T3 (da)	2007-01-15
CN1505511A (zh)	2004-06-16
PL366916A1 (en)	2005-02-07
CY1105813T1 (el)	2011-02-02
PT1385513E (pt)	2007-01-31
IL158266A (en)	2009-09-01
ES2254683T3 (es)	2006-06-16
RS50790B (sr)	2010-08-31
DE60208365D1 (de)	2006-02-02
EE200300465A (et)	2003-12-15
CZ20032910A3 (en)	2004-07-14
SK13242003A3 (sk)	2004-03-02
YU83403A (sh)	2006-08-17
FR2823975A1 (fr)	2002-10-31
HUP0400745A2 (hu)	2004-08-30
IL158312A (en)	2009-09-01
US20040122027A1 (en)	2004-06-24
US6967203B2 (en)	2005-11-22
YU83903A (sh)	2006-08-17
ZA200307785B (en)	2004-10-06
DE60208365T2 (de)	2006-09-07
DE60214533T2 (de)	2007-06-21
BR0209138A (pt)	2004-06-08
US7160895B2 (en)	2007-01-09
US20040122036A1 (en)	2004-06-24
MXPA03009639A (es)	2004-06-30
UA74876C2 (en)	2006-02-15
DK1385512T3 (da)	2006-05-22
WO2002087574A3 (fr)	2003-02-13
IL158312A0 (en)	2004-05-12
AR034313A1 (es)	2004-02-18
IS2441B (is)	2008-11-15
EP1385513A1 (fr)	2004-02-04
KR100847413B1 (ko)	2008-07-18
CZ20032909A3 (en)	2004-06-16
WO2002087575A1 (fr)	2002-11-07
JP2004531538A (ja)	2004-10-14
US7524857B2 (en)	2009-04-28
HK1059895A1 (en)	2004-07-23
EA200301062A1 (ru)	2004-04-29
PL366910A1 (en)	2005-02-07
CZ299465B6 (cs)	2008-08-06
DE60214533D1 (de)	2006-10-19
RU2003130376A (ru)	2005-04-10
NO20034785D0 (no)	2003-10-24
NO20034787D0 (no)	2003-10-24
ATE314070T1 (de)	2006-01-15
CA2443012C (fr)	2009-07-28
HK1060066A1 (en)	2004-07-30
CZ295224B6 (cs)	2005-06-15
US20050272760A1 (en)	2005-12-08

Legal Events

Date	Code	Title	Description
2004-06-16	C06	Publication
2004-06-16	PB01	Publication
2004-08-25	C10	Entry into substantive examination
2004-08-25	SE01	Entry into force of request for substantive examination
2006-02-08	C14	Grant of patent or utility model
2006-02-08	GR01	Patent grant
2011-06-29	C17	Cessation of patent right
2011-06-29	CF01	Termination of patent right due to non-payment of annual fee	Granted publication date: 20060208 Termination date: 20100426

Publication	Publication Date	Title
CN1144587C (zh)	2004-04-07	副作用减轻剂
US9555040B2 (en)	2017-01-31	Methods of treating proliferative diseases
CN103168042B (zh)	2015-10-21	7-([1,2,3]-***-4-基)吡咯并[2,3-b]吡嗪衍生物
KR20180113976A (ko)	2018-10-17	암을 치료하기 위한 테트라사이클릭 퀴놀론 유사체의 병행 요법
CN102369011A (zh)	2012-03-07	用于治疗造血恶性肿瘤的磷酸肌醇3-激酶抑制剂化合物与化学治疗剂的组合
JP2010533206A5 (da)	2011-09-01
KR20120000567A (ko)	2012-01-02	병용 요법을 이용한 치료 방법
CN102414211A (zh)	2012-04-11	3-([1,2,3]***-4-基)吡咯并[2,3-b]吡啶衍生物
CN103403005B (zh)	2016-02-03	5-([1,2,3]-***-4-基)-7H-吡咯并[2,3-d]嘧啶衍生物
CN1668298A (zh)	2005-09-14	抗肿瘤化合物及其治疗用途
CN1531435A (zh)	2004-09-22	抑制血管生成的方法
EP3991733A1 (en)	2022-05-04	Pharmaceutical composition for treating acute myeloid leukemia, containing flt3 inhibitor and chemotherapeutic agents
CN109819649B (zh)	2023-02-28	氨基嘌呤化合物的固体形式及其使用方法
CN111372934A (zh)	2020-07-03	Tg02的多晶型形式
CN1240382C (zh)	2006-02-08	以吡啶并吲哚酮衍生物和抗癌剂为基的药物组合
WO2015182628A1 (ja)	2015-12-03	ピラジンカルボキサミド化合物を有効成分とする医薬組成物
JP2018104290A (ja)	2018-07-05	ピラジンカルボキサミド化合物を有効成分とする医薬組成物
CN1302777C (zh)	2007-03-07	包括取代的丙烯酰偏端霉素衍生物和放射治疗的抗肿瘤联合疗法
WO2023099072A1 (en)	2023-06-08	Compounds
AU2022399786A1 (en)	2024-07-04	Compounds